Affiliation:
1. Shumakov National Medical Research Center of Transplantology and Artificial Organs;
Sechenov University
Abstract
Tacrolimus (TAC) is the primary drug for most immunosuppressive therapy regimens. It has a narrow therapeutic index, meaning that insufficient dose can lead to graft and tissue rejection, while overdose can lead to increased risk of infections, toxicity, and cancerous tumors in organ transplant recipients. TAC belongs to a group of calcineurin inhibitors inhibiting T-cell activation. The use of TAC requires regular clinical observation of recipients and laboratory monitoring of the drug concentrations in the blood. This is to ensure correct dosage of the drug and to limit the potential risk of harmful side effects. The review presents data on some clinical, genetic factors affecting the bioavailability and concentration of TAC in the blood. We also present data on the methodological aspects of TAC laboratory control.
Publisher
V.I. Shimakov Federal Research Center of Transplantology and Artificial Organs
Subject
Transplantation,Immunology and Allergy
Reference26 articles.
1. Immunosupressiya pri transplantatsii solidnykh organov / Pod red. S.V. Gautier. M.–Tver’: Triada, 2011. 472 s.: il.
2. Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert Opin Pharmacother. 2008; 9 (4): 635–643.
3. Gautier SV, Shevchenko AO, Popcov VN. Pacient s transplantirovannym serdcem. Rukovodstvo dlja vrachej po vedeniju pacientov, perenesshih transplantaciju serdca. M.–Tver’: Triada, 2014. 144.
4. Gao L, Liu J, Zhang Y et al. Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation. Leuk Res. 2017; 57: 27–36.
5. Maguire O, Tornatore KM, O’Loughlin KL et al. Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimus. Cytometry A. 2013; 83: 1096–1104.